A Phase 2/3 Trial of FG-4592 for Treatment of Anemia in Subjects With Lower Risk Myelodysplastic Syndrome
Not yet recruiting
Phase of Trial: Phase II/III
Latest Information Update: 27 Feb 2018
At a glance
- Drugs Roxadustat (Primary)
- Indications Anaemia
- Focus Registrational; Therapeutic Use
- Sponsors FibroGen
- 27 Feb 2018 According to a FibroGen media release, this trial is anticipated to start in in first half of 2018.
- 02 Oct 2017 Status changed from planning to not yet recruiting.
- 09 May 2017 According to a FibroGen media release, the company expects to initiate this trial in the fourth quarter of 2017.